Chris LeMasters

Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA.

Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ.

Adastra Pharmaceuticals, Inc. engages in the provision of clinical and commercial development of proprietary drugs for the treatment of various cancers. The company was founded by Tracy L. Parrott in 2005 and is headquartered in Princeton, NJ.

Promosome LLC is a biotechnology company specializing in technologies related to the regulation of protein synthesis through translation initiation. Its proprietary mRNA engineering technology exploits features of the natural translation process in both prokaryotic and eukaryotic cells. The technologies involve recoding mRNAs for biotherapeutic agents to enhance ribosome recruitment, eliminate false starts in translation initiation, and ensure message stability in both eukaryotic and prokaryotic cells. Promosome was founded by William J. Gedale and John R. Costantino in 2003 and is headquartered in New York, NY.

Aarden Pharmaceuticals, Inc. operated as a drug discovery and biotechnology company. The company was founded by Thomas M. Estok, Christopher C. LeMasters, Francis Burrows and Zhong-Yin Zhang in 2008 and was headquartered in Indianapolis, GA.

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.